Thabor Therapeutics Raises €2M in Financing

Thabor Therapeutics, a Paris, France-based company developing an innovative treatment for patients living with chronic mucosal inflammatory diseases, secured €2m ($2.09M) in funding.

French public investment bank Bpifrance provided the funds as part of the Deeptech Plan. The funding from Bpifrance is another step towards the series A round planned for Q4, 2022. Thabor also intends to use the money
This funding will enable the company to accelerate its R&D programs for the industrial development of its monoclonal antibodies and an IND (Investigational New Drug) application and for further staff recruitment to strengthen its team.

Led by Jérémie Mariau, CEO, Thabor Therapeutics is a biotech company which specializes in the development of an innovative approach to treat patients living with chronic mucosal inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). The company’s goal is to develop first-in-class drugs that specifically target newly identified gut-secreted proteins which disrupt epithelial homeostasis.
In 2021, the company received seed funding from AdBio partners. Based in Paris, the start-up was founded in June 2021 and currently employs six people.